Patient, disease, and transplantation characteristics
| Variables . | 8/8 PBPCs, n (%) . | 7/8 PBPCs, n (%) . | dUCB-TCF, n (%) . | dUCB-other, n (%) . | P . |
|---|---|---|---|---|---|
| No. of patients | 313 | 111 | 121 | 40 | |
| Age at transplantation, y | |||||
| Median (range) | 59 (23-69) | 58 (21-69) | 55 (23-68) | 48 (21-67) | < .0001 |
| 21-29 | 6 (2) | 7 (6) | 5 (4) | 3 (8) | < .0001 |
| 30-39 | 14 (4) | 4 (4) | 5 (4) | 7 (18) | |
| 40-49 | 38 (12) | 12 (11) | 22 (18) | 12 (30) | |
| 50-59 | 108 (35) | 43 (39) | 52 (43) | 9 (23) | |
| 60-69 | 147 (47) | 45 (41) | 37 (31) | 9 (23) | |
| Patient CMV | .07 | ||||
| Positive | 174 (56) | 67 (60) | 82 (68) | 31 (78) | |
| Negative | 135 (43) | 43 (39) | 39 (32) | 9 (23) | |
| Not reported | 4 (1) | 1 (1) | 0 | 0 | |
| Performance score before transplantation | .04 | ||||
| < 90% | 123 (39) | 44 (40) | 33 (27) | 17 (43) | |
| 90%-100% | 166 (53) | 59 (53) | 85 (70) | 21 (53) | |
| Not reported | 24 (8) | 8 (7) | 3 (2) | 2 (5) | |
| Disease | < .0001 | ||||
| Acute myeloid leukemia | 294 (94) | 100 (90) | 99 (82) | 30 (75) | |
| Acute lymphoblastic leukemia | 19 (6) | 11 (10) | 22 (18) | 10 (25) | |
| Disease status prior to transplantation | < .0001 | ||||
| CR1 | 165 (53) | 53 (48) | 74 (61) | 10 (25) | |
| CR2 | 65 (21) | 19 (17) | 33 (27) | 17 (43) | |
| CR3 | 9 (3) | 6 (5) | 7 (6) | 2 (5) | |
| PIF, relapse | 74 (24) | 33 (30) | 7 (6) | 11 (28) | |
| Conditioning regimen | < .0001 | ||||
| TBI + cy + fludarabine ± atg | 0 | 0 | 121 (100)k | 0 | |
| TBI + fludarabine ± atg | 76 (24)a | 20 (18)f | 0 | 0 | |
| TBI + fludarabine + bu ± atg | 8 (3)b | 5 (5)g | 0 | 8 (20)l | |
| Busulfan + fludarabine ± atg | 119 (38)c | 46 (41)h | 0 | 2 (5)m | |
| Melphalan + fludarabine ± atg | 84 (27)d | 30 (27)i | 0 | 28 (70)n | |
| Cyclophosphamide + fludarabine ± atg | 26 (8)e | 10 (9)j | 0 | 2 (5)o | |
| Year of transplantation | .006 | ||||
| 2000-2004 | 96 (31) | 29 (26) | 25 (21) | 3 (8) | |
| 2005-2009 | 217 (69) | 82 (74) | 96 (79) | 37 (93) | |
| Median follow-up of survivors, mo (range) | 35 (6-96) | 25 (6-75) | 25 (5-97) | 25 (6-61) |
| Variables . | 8/8 PBPCs, n (%) . | 7/8 PBPCs, n (%) . | dUCB-TCF, n (%) . | dUCB-other, n (%) . | P . |
|---|---|---|---|---|---|
| No. of patients | 313 | 111 | 121 | 40 | |
| Age at transplantation, y | |||||
| Median (range) | 59 (23-69) | 58 (21-69) | 55 (23-68) | 48 (21-67) | < .0001 |
| 21-29 | 6 (2) | 7 (6) | 5 (4) | 3 (8) | < .0001 |
| 30-39 | 14 (4) | 4 (4) | 5 (4) | 7 (18) | |
| 40-49 | 38 (12) | 12 (11) | 22 (18) | 12 (30) | |
| 50-59 | 108 (35) | 43 (39) | 52 (43) | 9 (23) | |
| 60-69 | 147 (47) | 45 (41) | 37 (31) | 9 (23) | |
| Patient CMV | .07 | ||||
| Positive | 174 (56) | 67 (60) | 82 (68) | 31 (78) | |
| Negative | 135 (43) | 43 (39) | 39 (32) | 9 (23) | |
| Not reported | 4 (1) | 1 (1) | 0 | 0 | |
| Performance score before transplantation | .04 | ||||
| < 90% | 123 (39) | 44 (40) | 33 (27) | 17 (43) | |
| 90%-100% | 166 (53) | 59 (53) | 85 (70) | 21 (53) | |
| Not reported | 24 (8) | 8 (7) | 3 (2) | 2 (5) | |
| Disease | < .0001 | ||||
| Acute myeloid leukemia | 294 (94) | 100 (90) | 99 (82) | 30 (75) | |
| Acute lymphoblastic leukemia | 19 (6) | 11 (10) | 22 (18) | 10 (25) | |
| Disease status prior to transplantation | < .0001 | ||||
| CR1 | 165 (53) | 53 (48) | 74 (61) | 10 (25) | |
| CR2 | 65 (21) | 19 (17) | 33 (27) | 17 (43) | |
| CR3 | 9 (3) | 6 (5) | 7 (6) | 2 (5) | |
| PIF, relapse | 74 (24) | 33 (30) | 7 (6) | 11 (28) | |
| Conditioning regimen | < .0001 | ||||
| TBI + cy + fludarabine ± atg | 0 | 0 | 121 (100)k | 0 | |
| TBI + fludarabine ± atg | 76 (24)a | 20 (18)f | 0 | 0 | |
| TBI + fludarabine + bu ± atg | 8 (3)b | 5 (5)g | 0 | 8 (20)l | |
| Busulfan + fludarabine ± atg | 119 (38)c | 46 (41)h | 0 | 2 (5)m | |
| Melphalan + fludarabine ± atg | 84 (27)d | 30 (27)i | 0 | 28 (70)n | |
| Cyclophosphamide + fludarabine ± atg | 26 (8)e | 10 (9)j | 0 | 2 (5)o | |
| Year of transplantation | .006 | ||||
| 2000-2004 | 96 (31) | 29 (26) | 25 (21) | 3 (8) | |
| 2005-2009 | 217 (69) | 82 (74) | 96 (79) | 37 (93) | |
| Median follow-up of survivors, mo (range) | 35 (6-96) | 25 (6-75) | 25 (5-97) | 25 (6-61) |
PBPC indicates peripheral blood progenitor cell; CR, complete remission; PIF, primary induction failure; TBI, total body irradiation; and atg, antithymocyte globulin.
8/8 HLA-matched PBPC regimens: aTBI + fludarabine: 1 of 76 received ATG; bTBI + busulfan + fludarabine: 1 of 8 received ATG; cBusulfan + fludarabine: 78 of 119 received ATG; dMelphalan + fludarabine: 26 of 84 received ATG; and eCyclophosphamide + fludarabine: 1 of 26 received ATG.
7/8 HLA-matched PBPC regimens: fTBI + fludarabine: 3 of 20 received ATG; gTBI + busulfan + fludarabine: 1 of 5 received ATG; hBusulfan + fludarabine: 28 of 46 received ATG; iMelphalan + fludarabine: 14 of 30 received ATG; and jCyclophosphamide + fludarabine: none received ATG.
dUCB-TCF regimens: k38 of 120 patients received ATG.
dUCB-other regimens: lNone received ATG; m1 of 2 patients received ATG; n27 of 28 patients received ATG; 13 of 28 received thiotepa; and 1 of 2 patients received ATG.